MIRA Pharmaceuticals, Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
Severe listing-compliance risk
The share price is below $1 and the stored reverse-split/listing-risk level is HIGH. No verified reverse-split authorization or announced reverse split is currently recorded. This is a risk signal, not confirmation that Nasdaq has issued a deficiency notice.
MIRA · Price history
Price at last available close
$0.56
−$0.32 (-36.19%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About MIRA Pharmaceuticals, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia.
How they make money
MIRA Pharmaceuticals is a clinical-stage pharmaceutical development company that does not currently generate revenue from product sales. Its business model relies on raising capital to fund the research and development of a pipeline of novel oral therapeutics targeting neurologic, neuropsychiatric, metabolic, and addiction-related disorders.
Products & services
The company is developing a pipeline of drug candidates including MIRA-55, Ketamir-2, and SKNY-1, which are in preclinical or clinical stages for treating pain, depression, PTSD, and cognitive function.
Brands & revenue mix
Lead preclinical-stage oral therapeutic candidate for pain and inflammation.
Separate brand revenue is not available in this research.Source
Clinical-stage drug candidate for neurologic and neuropsychiatric disorders.
Separate brand revenue is not available in this research.Source
Preclinical-stage oral therapeutic candidate targeting CB1/CB2 receptors and MAO-B.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct preclinical and clinical trials.Source
Strengths
- Exclusive rights to novel drug candidates Ketamir-2 and MIRA-55 in North AmericaSource
Sources
Company-specific research
Questions worth answering for MIRA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can MIRA fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is MIRA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for MIRA to reach sustainable profitability?
- •What future growth or profitability would be needed to justify MIRA's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of MIRA's score?
Essential Investment Snapshot
Market Cap
$23.4M
P/E Ratio
-0.5
EPS
$-1.38
52-Week High
$2.45
52-Week Low
$0.60
Beta
1.53
Shares Outstanding
23.7M
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$0.34
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on MIRA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Exclusive rights to novel drug candidates Ketamir-2 and MIRA-55 in North America.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - General industry.
- −History of operating losses and expectation of continued losses.
- −Dependence on successful clinical trials and regulatory approval.
- −Diluted weighted-average shares increased 147.4% year over year.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$0.56
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· |
| Research & Development | $2.1M | $1.7M | $3.3M | $1.6M | ···· | ···· | ···· |
| SG&A Expenses | $7.3M | $8.8M | $4.7M | $6.5M | ···· | ···· | ···· |
| Operating Expenses | $9.4M | $10.5M | $8.0M | $8.5M | ···· | ···· | ···· |
| EBITDA | -$9.4M | -$10.4M | -$8.0M | -$8.5M | ···· | ···· | ···· |
| Operating Income | -$9.4M | -$10.5M | -$8.0M | -$8.5M | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $166K | $3.5M | ···· | ···· | ···· |
| Income Before Tax | -$9.5M | -$10.4M | -$7.9M | -$12.0M | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· |
| Net Income | -$9.5M | -$10.4M | -$7.9M | -$12.0M | ···· | ···· | ···· |
| Basic EPS | $-1.38 | $-1.35 | $-0.51 | $-0.65 | ···· | ···· | ···· |
| Basic Shares | 42.02M | 23.69M | 15.44M | 18.57M | ···· | ···· | ···· |
| Diluted Shares | 42.02M | 23.69M | 15.44M | 18.57M | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.03
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
+394.1%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
Potential Score Impact
Positive indicators included cash levels. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 68.2%. Cash increased 394.1%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - GeneralNews
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Miravalles Gold Corp. Files NI 43-101 Technical Report for Fairfield Gold Project, Nayarit, Mexico
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
Rumor Mill · MIRA
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial